990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort

Abstract

Non-small cell lung cancer (NSCLC) with EGFR mutations exhibits a higher incidence of central nervous system (CNS) metastasis. Although radiotherapy (RT) is a standard treatment for CNS metastasis, it delays the start of systemic chemotherapy, and whole brain RT carries a risk of cognitive dysfunction. The aim of the study was to assess osimertinib for patients with RT-naïve CNS metastasis of EGFR mutations positive NSCLC. This study was two-cohort trial, we previously reported about 'T790M cohort', and here we report the results of '1st-line cohort'.